Physician profile
Chloe Gaines
NPI 1073053781
$2,170.02
in general payments reported to CMS, 2019-2025
24 companies · $632 in 2025
The $632 reported for 2025 was more than what 81% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.83 · 2022: $491 · 2023: $258 · 2024: $771 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.57 |
| Education | $215.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $484.30 | 2022-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $252.60 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $196.57 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $171.03 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $160.94 | 2024-2025 | |
| Verona Pharma, INC. | $103.22 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $102.64 | 2021-2023 | Yupelri |
| Axsome Therapeutics, INC. | $96.76 | 2024-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $89.95 | 2022-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $82.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $64.98 | 2022-2023 | Airduo Digihaler |
| Abbvie INC. | $44.30 | 2025 | |
| Electromed, INC. | $41.36 | 2022 | |
| Lilly USA, LLC | $38.69 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $34.13 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $32.84 | 2025 | Inspire |
| Insmed, INC. | $32.46 | 2025 | Arikayce |
| Inogen, INC. | $26.34 | 2022 | |
| Gilead Sciences, INC. | $24.37 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.22 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $21.37 | 2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $16.95 | 2024 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.22 | 2022 | |
| Vifor Pharma, INC. | $14.70 | 2025 | Zemaira |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Gaines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.